» Articles » PMID: 20528123

Pathogenesis and Diagnosis of Hepatic Encephalopathy

Overview
Specialty Gastroenterology
Date 2010 Jun 10
PMID 20528123
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic encephalopathy (HE) is a common and potentially devastating neuropsychiatric complication of acute liver failure and cirrhosis. Even in its mildest form, minimal HE (MHE), the syndrome significantly impacts daily living and heralds progression to overt HE. There is maturity in the scientific understanding of the cellular processes that lead to functional and structural abnormalities in astrocytes. Hyperammonemia and subsequent cell swelling is a key pathophysiological abnormality, but this aspect alone is insufficient to fully explain the complex neurotransmitter abnormalities that may be observable using sophisticated imaging techniques. Inflammatory cytokines, reactive oxygen species activation and the role of neurosteroids on neurotransmitter binding sites are emerging pathological lines of inquiry that have yielded important new information on the processes underlying HE and offer promise of future therapeutic targets. Overt HE remains a clinical diagnosis and the neurophysiological and imaging modalities used in research studies have not transferred successfully to the clinical situation. MHE is best characterized by psychometric evaluation, but these tests can be lengthy to perform and require specific expertise to interpret. Simpler computer-based tests are now available and perhaps offer an opportunity to screen, diagnose and monitor MHE in a clinical scenario, although large-scale studies comparing the different techniques have not been undertaken. There is a discrepancy between the depth of understanding of the pathophysiology of HE and the translation of this understanding to a simple, easily understood diagnostic and longitudinal marker of disease. This is a present area of focus for the management of HE.

Citing Articles

Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy.

Perrone V, Usala M, Veronesi C, Cappuccilli M, Degli Esposti L Medicina (Kaunas). 2025; 61(2).

PMID: 40005338 PMC: 11857196. DOI: 10.3390/medicina61020221.


Quantitative susceptibility mapping reveals brain iron accumulation in minimal hepatic encephalopathy: associations with neurocognitive changes.

Cai L, Zeng J, Huang H, Tang Y, Li D, Li J Metab Brain Dis. 2024; 40(1):22.

PMID: 39565400 DOI: 10.1007/s11011-024-01440-6.


Decreased Expression and Uncoupling of Endothelial Nitric Oxide Synthase in the Cerebral Cortex of Rats with Thioacetamide-Induced Acute Liver Failure.

Milewski K, Czarnecka A, Albrecht J, Zielinska M Int J Mol Sci. 2021; 22(13).

PMID: 34206365 PMC: 8268495. DOI: 10.3390/ijms22136662.


Role of Brain Biomarkers S-100-Beta and Neuron-Specific Enolase for Detection and Follow-Up of Hepatic Encephalopathy in Cirrhosis before, during and after Treatment with L-Ornithine-L-Aspartate.

Strebel H, Haller B, Sohn M, Schepp W, Gundling F GE Port J Gastroenterol. 2020; 27(6):391-403.

PMID: 33251288 PMC: 7670347. DOI: 10.1159/000507225.


Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy.

Han W, Zhang H, Han Y, Duan Z Metab Brain Dis. 2020; 35(6):869-881.

PMID: 32495311 PMC: 7354280. DOI: 10.1007/s11011-020-00539-w.